My presentation will discuss drug discovery and clinical development results obtained in two different program targeting disorders with high unmet need: GlyT1 inhibitor program for the treatment of schizophrenia that reached phase III studies [1] with bitopertin [2] and SMN2 splicing modifier program that led to the identification of RG7800 for the treatment of SMA (Spinal Muscular Atrophy) [3],[4].

[1] Biol. Psychiatry, 2017, 82, 8-16
[2] J. Med. Chem., 2010, 53, 4603-4614
[3] J. Med. Chem., 2016, 59, 6086-6100
[4] J. Med. Chem., 2017, 60, 4444-4457    

The KGF-SCS Senior Industrial Science Award is given to Dr. Emmanuel Pinard, F. Hoffmann-La Roche Ltd, Basel, for his very successful research on several therapeutic targets as enzymes (Bace1, COMT), ion channels (NMDA), GPCRs (Orexin, Vasopressin) and transporters (GlyT1) that address high unmet central nervous system disorders such as Parkinson’s Disease, Stroke, Schizophrenia, Depression, Autism and Spinal Motor Atrophy.